- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01865032
Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis
September 5, 2014 updated by: U.S. Army Medical Research and Development Command
Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States
This study is a single-site trial assessing the specificity of CL Detect™ Rapid Test versus the gold standard for Leishmania diagnosis in the US which is microscopic identification of Leishmania amastigotes in a stained lesion sample.
Subjects will be patients who present for dermatology consultation with a primarily ulcerated lesion.
After informed consent is obtained and the subject is screened for eligibility, 2 diagnostic samples will be collected from the subject's lesion in the following order: 1) one sample will be obtained with a dental broach for use with the CL Detect™ Rapid Test and 2) a second sample will be obtained by scraping for use in the microscopic identification of amastigotes.
Samples will be analyzed by microscopy and CL Detect™ Rapid Test.
The CL Detect™ Rapid Test will be performed by different operators who are clinical staff members.
These staff members, blinded to each other's results, will evaluate the samples from each method independently.
Each of the 150 study subjects will be followed administratively to the point where a diagnosis is established (if possible) for their tested lesion, even if that diagnosis is not cutaneous leishmaniasis (CL).
If a specific diagnosis cannot be determined for a non-CL lesion, the investigator will assign a "likely etiology" (eg, infectious, oncological, immunological, vascular, or "undetermined/other" origin).
Based on the diagnosis determined for each lesion, subjects will be referred for appropriate treatment.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Dermatology clinic
Description
Inclusion Criteria:
- At least 18 years of age
- Subject is able to give written informed consent
- Subject has a skin ulcer that satisfies the following criteria for an index lesion:
- less than 4 months in age
- primarily ulcerative, not purely verrucous or nodular, and does not have clear clinical evidence of cellulitis
- in a location suitable for collecting samples by dental broach and scraping
- In the opinion of the investigator, the subject is capable of understanding and complying with the protocol
Exclusion Criteria:
- Received treatment for leishmaniasis or any treatment to the lesion even if not previously diagnosed as leishmaniasis such as azoles, cryotherapy, imiquimod, thermotherapy, photodynamic therapy, within 2 months prior to signing the consent form, with the exception of mercurochrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Skin Ulcers
Skin ulcers.
No intervention.
Subjects will be followed up by their respective primary providers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity
Time Frame: 1 hour
|
Specificity will be presented for the CL Detect™ Rapid Test device against the reference method (microscopy).
Specificity will be calculated as the number of true negatives divided by the sum of the number of true negatives plus the number of false positives times 100%.
|
1 hour
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
False positive rate
Time Frame: 1 hour
|
α, type 1 error, calculated as 1-specificity times 100%
|
1 hour
|
False negative rate
Time Frame: 1 hour
|
β, type 2 error, calculated as 1-sensitivity times 100%
|
1 hour
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
April 1, 2014
Study Registration Dates
First Submitted
May 23, 2013
First Submitted That Met QC Criteria
May 28, 2013
First Posted (Estimate)
May 30, 2013
Study Record Updates
Last Update Posted (Estimate)
September 8, 2014
Last Update Submitted That Met QC Criteria
September 5, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-12-19
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Diseases
-
West Virginia UniversityMary Babb Randolph Cancer Center at West Virginia University Hospitals; West...RecruitingSkin Cancer | Skin Lesion | Skin Melanoma | Tumor SkinUnited States
-
R2 DermatologyCompleted
-
TCI Co., Ltd.Completed
-
Access Business GroupClinical Research LaboratoriesCompleted
-
Paratek Pharmaceuticals IncCompletedInfectious Skin Disease | Bacterial Skin DiseaseUnited States
-
Molnlycke Health Care ABCompletedPsoriasis | Eczema | Dry Skin; EczemaUnited Kingdom